Erbitux Improves Survival In Metastatic Colorectal Cancer - Study
Medical News Today - Merck Serono has leading brands serving patients with cancer (Erbitux®), multiple sclerosis (Rebif®), infertility (Gonal-f®), metabolic and cardiometabolic disorders (Glucophage®, Concor®, Saizen®, Serostim®), as well as psoriasis (Raptiva
Wednesday, November 21, 2007
Erbitux Improves Survival In Metastatic Colorectal Cancer - Study
Bookmark this post:
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment